Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Phase 1/2 Completed 25 enrolled Queen's Medical Center National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer.

Timeline

Start: 2009-06
Primary completion: 2016-06
Completion: 2016-06

Publications

Lee J, Sato MM, Coel MN, Lee KH, Kwee SA. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT. J Nucl Med. 2016 Jul;57(7):1058-64. doi: 10.2967/jnumed.115.169177. Epub 2016 Feb 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	methylcholine	Diagnostic / imaging agent	—	Intravenous

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications